US 11,884,718 B2
Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
Shelly Krebs, Bethesda, MD (US); Gina Donofrio, Rockville, MD (US); Vincent Dussupt, Silver Spring, MD (US); Kayvon Modjarrad, Bethesda, MD (US); Dan Barouch, Boston, MA (US); Richard G. Jarman, III, Silver Spring, MD (US); Nelson L. Michael, Silver Spring, MD (US); Gordon Joyce, Silver Spring, MD (US); Rajeshwer Singh Sankhala, Silver Spring, MD (US); and Kathryn Elaine Stephenson, Boston, MA (US)
Assigned to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US); The Beth Israeli Deaconess Medical Center, Inc., Boston, MA (US); and The Government Of The United States As Represented By The Secretary Of The Army, Fort Detrick, MD (US)
Appl. No. 17/049,800
Filed by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US); The Beth Israel Deaconess Medical Center, Inc., Boston, MA (US); and The Government of the United States as Represented by the Secretary of the Army, Silver Spring, MD (US)
PCT Filed Apr. 24, 2019, PCT No. PCT/US2019/028952
§ 371(c)(1), (2) Date Oct. 22, 2020,
PCT Pub. No. WO2019/209974, PCT Pub. Date Oct. 31, 2019.
Claims priority of provisional application 62/697,347, filed on Jul. 12, 2018.
Claims priority of provisional application 62/662,211, filed on Apr. 24, 2018.
Prior Publication US 2021/0238262 A1, Aug. 5, 2021
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); G01N 33/563 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1081 (2013.01) [A61K 39/12 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); G01N 33/563 (2013.01); G01N 33/56983 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5252 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2770/24134 (2013.01)] 17 Claims
 
1. An antibody or fragment thereof that selectively binds Zika virus, wherein said antibody comprises:
(a) a heavy chain variable region comprising complementarity determining regions (CDRs) having amino acid sequences SEQ ID NO: 5 for CDR1, SEQ ID NO: 6 for CDR2, and SEQ ID NO: 7 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 8 for CDR1, SEQ ID NO: 9 for CDR2 and SEQ ID NO: 10 for CDR3; or
(b) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 15 for CDR1, SEQ ID NO: 16 for CDR2, and SEQ ID NO: 17 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 18 for CDR1, SEQ ID NO: 19 for CDR2 and SEQ ID NO: 20 for CDR3; or
(c) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 25 for CDR1, SEQ ID NO: 26 for CDR2, and SEQ ID NO: 27 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 28 for CDR1, SEQ ID NO: 29 for CDR2 and SEQ ID NO: 30 for CDR3; or
(d) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 35 for CDR1, SEQ ID NO: 36 for CDR2, and SEQ ID NO: 37 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 38 for CDR1, SEQ ID NO: 39 for CDR2 and SEQ ID NO: 40 for CDR3; or
(e) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 45 for CDR1, SEQ ID NO: 46 for CDR2, and SEQ ID NO: 47 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 48 for CDR1, SEQ ID NO: 49 for CDR2 and SEQ ID NO: 50 for CDR3; or
(f) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 55 for CDR1, SEQ ID NO: 56 for CDR2, and SEQ ID NO: 57 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 58 for CDR1, SEQ ID NO: 59 for CDR2 and SEQ ID NO: 60 for CDR3; or
(g) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 65 for CDR1, SEQ ID NO: 66 for CDR2, and SEQ ID NO: 67 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 68 for CDR1, SEQ ID NO: 69 for CDR2 and SEQ ID NO: 70 for CDR3; or
(h) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 75 for CDR1, SEQ ID NO: 76 for CDR2, and SEQ ID NO: 77 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 78 for CDR1, SEQ ID NO: 79 for CDR2 and SEQ ID NO: 80 for CDR3; or
(i) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 85 for CDR1, SEQ ID NO: 86 for CDR2, and SEQ ID NO: 87 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 88 for CDR1, SEQ ID NO: 89 for CDR2 and SEQ ID NO: 90 for CDR3; or
(j) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 95 for CDR1, SEQ ID NO: 96 for CDR2, and SEQ ID NO: 97 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 98 for CDR1, SEQ ID NO: 99 for CDR2 and SEQ ID NO: 100 for CDR3; or
(k) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 105 for CDR1, SEQ ID NO: 106 for CDR2, and SEQ ID NO: 107 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 108 for CDR1, SEQ ID NO: 109 for CDR2 and SEQ ID NO: 110 for CDR3; or
(l) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 115 for CDR1, SEQ ID NO: 116 for CDR2, and SEQ ID NO: 117 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 118 for CDR1, SEQ ID NO: 119 for CDR2 and SEQ ID NO: 120 for CDR3; or
(m) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 125 for CDR1, SEQ ID NO: 126 for CDR2, and SEQ ID NO: 127 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 128 for CDR1, SEQ ID NO: 129 for CDR2 and SEQ ID NO: 130 for CDR3; or
(n) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 135 for CDR1, SEQ ID NO: 136 for CDR2, and SEQ ID NO: 137 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 138 for CDR1, SEQ ID NO: 139 for CDR2 and SEQ ID NO: 140 for CDR3; or
(o) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 145 for CDR1, SEQ ID NO: 146 for CDR2, and SEQ ID NO: 147 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 148 for CDR1, SEQ ID NO: 149 for CDR2 and SEQ ID NO: 150 for CDR3; or
(p) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 155 for CDR1, SEQ ID NO: 156 for CDR2, and SEQ ID NO: 157 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 158 for CDR1, SEQ ID NO: 159 for CDR2 and SEQ ID NO: 160 for CDR3; or
(q) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 165 for CDR1, SEQ ID NO: 166 for CDR2, and SEQ ID NO: 167 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 168 for CDR1, SEQ ID NO: 169 for CDR2 and SEQ ID NO: 170 for CDR3; or
(r) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 175 for CDR1, SEQ ID NO: 176 for CDR2, and SEQ ID NO: 177 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 178 for CDR1, SEQ ID NO: 179 for CDR2 and SEQ ID NO: 180 for CDR3; or
(s) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 185 for CDR1, SEQ ID NO: 186 for CDR2, and SEQ ID NO: 187 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 188 for CDR1, SEQ ID NO: 189 for CDR2 and SEQ ID NO: 190 for CDR3; or
(t) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 195 for CDR1, SEQ ID NO: 196 for CDR2, and SEQ ID NO: 197 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 198 for CDR1, SEQ ID NO: 199 for CDR2 and SEQ ID NO: 200 for CDR3; or
(u) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 205 for CDR1, SEQ ID NO: 206 for CDR2, and SEQ ID NO: 207 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 208 for CDR1, SEQ ID NO: 209 for CDR2 and SEQ ID NO: 210 for CDR3; or
(v) a heavy chain variable region comprising CDRs having amino acid sequences SEQ ID NO: 215 for CDR1, SEQ ID NO: 216 for CDR2, and SEQ ID NO: 217 for CDR3; and a light chain variable region comprising CDRs having amino acid sequences of SEQ ID NO: 218 for CDR1, SEQ ID NO: 219 for CDR2 and SEQ ID NO: 220 for CDR3.